Justia Native American Law Opinion Summaries

This case involves a dispute between two tribally owned businesses, AQuate II, LLC and Kituwah Services, LLC, both of which compete for federal contracts under the Small Business Administration’s 8(a) Business Development Program. AQuate alleges that Kituwah and its employee, Jessica Myers, stole trade secrets related to a government contract that AQuate had won in the past. AQuate claims that Myers, a former employee, breached her employment agreements and violated both the Defend Trade Secrets Act of 2016 and the Alabama Trade Secrets Act. Kituwah, however, argues that it is shielded by tribal sovereign immunity, while Myers contends that her employment contract mandates that any claims against her can only be brought in a designated tribal court.The United States District Court for the Northern District of Alabama dismissed the case, finding that Kituwah had not waived sovereign immunity for the trade secrets claims and that the claims against Myers should be resolved in the Alabama-Quassarte Tribal Town court, as stipulated in her employment contract. AQuate appealed the decision, arguing that the tribal court did not exist.The United States Court of Appeals for the Eleventh Circuit reversed the district court’s decision. The appellate court found that Kituwah had waived sovereign immunity for claims related to the federal contracting program and could be sued. Regarding Myers, the court determined that the district court failed to consider whether the clause naming the allegedly nonexistent tribal court as the appropriate forum was valid and enforceable. The case was remanded for further consideration. View "Aquate II, LLC v. Myers" on Justia Law

Allergan’s Restasis Patents relate to a treatment for alleviating the symptoms of chronic dry eye. In 2015, Allergan sued, alleging infringement of the Restasis Patents based on Mylan’s filings of Abbreviated New Drug Applications. Mylan, Teva, and Akorn sought inter partes review of the patents. The Patent Board instituted IPR and scheduled a consolidated oral hearing. Before the hearing, Allergan and the Tribe entered into an agreement Mylan alleges was intended to protect the patents from review. A patent assignment transferring the Restasis patents from Allergan to the Tribe was recorded with the Patent Office. The Tribe moved to terminate the IPRs, arguing it is entitled to assert tribal sovereign immunity; Allergan moved to withdraw. The Board denied both motions. The Federal Circuit affirmed. IPR is neither clearly a judicial proceeding instituted by a private party nor clearly an enforcement action brought by the federal government: tribal sovereign immunity may not be asserted in IPR proceedings. View "Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals Inc." on Justia Law